Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

WuXi Biologics and Boostimmune Forge Exclusive R&D Partnership

Fineline Cube Aug 11, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...

Company Deals

Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China

Fineline Cube Aug 11, 2023

China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...

Company

Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales

Fineline Cube Aug 11, 2023

Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the...

Company Legal / IP

Pfizer Faces Whistleblower Lawsuit Over Alleged FCPA Violations in China

Fineline Cube Aug 11, 2023

A former employee of Pfizer Inc., (NYSE: PFE), Frank Han, has filed a civil lawsuit...

Company

Organon Reports Q2 2023 Revenue Growth, Driven by Women’s Health and Biosimilars

Fineline Cube Aug 10, 2023

US-based Organon (NYSE: OGN) has reported its financial results for the second quarter of 2023,...

Company Deals

Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US...

Company

Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...

Company Deals

Poseida Therapeutics Secures $50 Million Investment from Astellas for Cell and Gene Therapy

Fineline Cube Aug 10, 2023

US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Completes Phase III Study for Myopia Treatment NVK002

Fineline Cube Aug 10, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Company Medical Device

Eyebright Medical Technology’s Intraocular Lenses Earn Fast-Track Status in China

Fineline Cube Aug 10, 2023

Beijing-based Eyebright Medical Technology Co., Ltd (SHE: 688050) has announced that its “intraocular lenses with...

Company Deals

Neurophth Biotechnology Secures RMB700 Million in Series C+ Financing for Gene Therapy Development

Fineline Cube Aug 10, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has reportedly secured close to RMB700 million in...

Company Drug

Novartis Reports Positive Phase III Results for Remibrutinib in Chronic Spontaneous Urticaria

Fineline Cube Aug 10, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has announced positive data from the Phase III...

Company Deals

Burning Rock Partners with AstraZeneca to Develop Companion Diagnostics for Cancer Therapies

Fineline Cube Aug 9, 2023

Guangzhou-based medical device giant Burning Rock (NASDAQ: BNR) has announced a strategic partnership with AstraZeneca...

Company Policy / Regulatory

Audit Reveals Illicit Payments and Inflated Prices in Pharmaceutical Industry

Fineline Cube Aug 9, 2023

An audit has shed light on the use of third-party business promotion companies as a...

Company

Eli Lilly & Co. Reports 28% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 9, 2023

US pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) has released its financial results for...

Company

FibroGen’s Evrenzo Achieves Record Sales in China, Outlook for 2024 Remains Promising

Fineline Cube Aug 9, 2023

US-based biopharmaceutical company FibroGen Inc., (NASDAQ: FGEN) has released its financial report for the second...

Company

Bayer AG Reports Q2/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals

Fineline Cube Aug 9, 2023

Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter...

Company Drug

Novo Nordisk’s Wegovy Demonstrates 20% Reduction in Cardiovascular Events in SELECT Trial

Fineline Cube Aug 9, 2023

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has released topline data supporting the use...

Policy / Regulatory

Shanghai Health Commission Issues Regulations to Curb Unhealthy Pharmaceutical Practices

Fineline Cube Aug 9, 2023

In alignment with the No. 75 Document by the National Health Commission, the Shanghai...

Company Deals

CanSino Biotechnology Partners with AstraZeneca for mRNA Vaccine Development and Manufacturing

Fineline Cube Aug 9, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced a product supply cooperation framework...

Posts pagination

1 … 544 545 546 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.